Chrysin was obtained from Sigma-Aldrich (Sigma-Aldrich, Cat No. C80105, St. Louis, MO, USA).BrMC was synthesized with previously described protocols [
20].EGF (Carlsbad, CA, USA, 0.1 μg/mL), bFGF (0.1 μg/mL) and B27 (without Vitamin A) from Invitrogen. Accutase from PromoCell (Cat No. C-41310, Germany), insulin was purchased from Sigma-Aldrich. Additional reagents were: horseradish peroxidase (HRP)-conjugated anti-mouse or anti-rabbit secondary antibodies (1:2000) (Cat. No. A0216 and A0239, respectively; Beyotime Institute of Biotechnology, Shang Hai, China); Rabbit anti-human CD133 polyclonal antibody (1:2000), CD44 and α-SMA(1:2000), No. ab66141, No. ab41478, No.ab75273,Abcam,Inc.,Burlingame,CA,USA; β-actin (1:2000), FAP-α(1:2000) and IL-6 neutralizing antibody, Cat. No. sc-7210, Cat.No.sc-54,538,Cat.No.sc-57,315, Santa Cruz Biotechnology, Inc. Beverly, MA, USA; HGF neutralizing antibody, Cat.No.ab24865, Abcam Company, Cambridge, MA, USA; human recombinant IL-6 and human recombinant HGF, Cat. No. 200–06, Cat.No.100–39, PeproTech Inc. Rocky Hill, NJ, USA; and enhanced chemiluminescence detection reagent (ECL), Amersham Pharmacia Biotech, USA; ELISA kits, Neobioscience, Shenzhen, Guangdong, China.